Table 1.
Vitamin D metabolites in preclinical models of infantile hypercalcemia type 1.
| Strain/Genotype | Sex | 25(OH)D3 (ng/mL) |
24,25(OH)2D3 (ng/mL) |
Ratio 25:24,25 |
1,24,25(OH)3D3 (pg/mL) |
25(OH)D3-26,23-lactone (ng/mL) |
1,25(OH)2D3 (pg/mL) |
|---|---|---|---|---|---|---|---|
| Cyp24a1 +/− | m | – | – | – | – | – | - |
| f | 17.21 ± 2.36 | 6.68 ± 1.05 | 2.60 ± 0.10 | 72.80 ± 4.20 | 3.84 ± 0.72 | 27.80 ± 4.20 | |
| Cyp24a1 −/− | m | – | – | – | – | – | – |
| f | 101.29 ± 20.61 *** | 1.45 ± 0.11 *** | 70.60 ± 15.7 # | n.d. | 0.06 ± 0.02 # | 34.00 ± 6.20 | |
| C57bl6-R396+/+ | m | 19.59 ± 2.90 | 6.71 ± 0.76 | 2.91 ± 0.33 | 57.77 ± 10.88 | 2.76 ± 0.32 | 27.39 ± 3.35 |
| f | 18.59 ± 2.50 | 7.38 ± 0.96 | 2.53 ± 0.25 | 66.53 ± 13.18 | 3.16 ± 0.89 | 21.28 ± 5.96 | |
| C57bl6-R396w/w | m | 110.73 ± 15.40 # | 2.59 ± 0.44 # | 43.10 ± 4.08 # | 17.81 ± 3.53 # | 0.07 ± 0.03 # | 37.06 ± 8.85 |
| f | 106.16 ± 26.73 # | 2.12 ± 0.44 # | 49.71 ± 4.37 # | 11.09 ± 5.35 # | 0.05 ± 0.02 # | 37.17 ± 12.12 ** | |
| CD1-R396+/+ | m | 17.23 ± 3.77 | 6.31 ± 1.89 | 2.94 ± 1.07 | 74.66 ± 34.78 | 2.24 ± 0.70 | 45.83 ± 22.74 |
| f | 18.24 ± 4.14 | 8.80 ± 2.14 | 2.08 ± 0.19 | 55.19 ± 17.50 | 2.56 ± 0.67 | 27.43 ± 9.77 | |
| CD1-R396w/w | m | 81.90 ± 19.39 # | 2.26 ± 0.53 # | 36.58 ± 5.35 # | 15.18 ± 5.84 # | 0.06 ± 0.05 # | 45.12 ± 16.57 |
| f | 99.16 ± 13.59 # | 2.23 ± 0.39 # | 44.90 ± 5.53 # | 7.49 ± 1.95 # | 0.03 ± 0.01 # | 29.24 ± 7.98 |
Results are means ± S.D. Ratio 25:24,25, ratio of 25(OH)2D3 concentrations over 24,25(OH)2D3 concentrations. n.d., non-detectable. **, p < 0.01; ***, p < 0.001; #, p < 0.0001 vs. corresponding wild-type sex within strain by 2-way ANOVA and Sidak’s post hoc test.